- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03284762
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)
November 20, 2020 updated by: Bayer
Xarelto® on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice.
Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study takes place in Korea and Taiwan.
Approximately a total of 1200 patients will be included in the study within 12 months.
The observation period for each patient is 1 year from enrollment into the study, or until withdrawal of consent or lost to follow-up.
Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
Study Type
Observational
Enrollment (Actual)
1216
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Multiple Locations, Korea, Republic of
- Different facilities
-
-
-
-
-
Multiple Locations, Taiwan
- Different facilities
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients from Taiwan and Korea visiting doctors in hospitals or medical practices for treatment of atrial fibrillation
Description
Inclusion Criteria:
- Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)
- Diagnosis of NVAF
- Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice
- Treatment naïve regarding stroke prevention for atrial fibrillation
- Signed informed consent
Exclusion Criteria:
- Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)
- Patients participating in an investigational program with interventions outside of routine clinical practice
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment-naïve NVAF patients in Korea and Taiwan
Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
NVAF: Non-valvular atrial fibrillation
|
Rivaroxaban is a direct Factor Xa inhibitor.
In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major bleeding events, collected as Serious Adverse Events (SAEs) or non-serious Adverse Events (AEs)
Time Frame: Up to one year
|
Major bleeding events, collected as SAEs or non-serious AEs and defined as overt bleeding associated with:
|
Up to one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AEs
Time Frame: Up to one year
|
All events which do not fall under characterization of major bleeding events as explained in section "primary outcome variables"
|
Up to one year
|
SAEs
Time Frame: Up to one year
|
All events which do not fall under characterization of major bleeding events as explained in section "primary outcome variables"
|
Up to one year
|
All-cause mortality
Time Frame: Up to one year
|
All events which do not fall under characterization of major bleeding events as explained in section "primary outcome variables"
|
Up to one year
|
Non-major bleeding events
Time Frame: Up to one year
|
All events which do not fall under characterization of major bleeding events as explained in section "primary outcome variables"
|
Up to one year
|
Symptomatic thromboembolic events
Time Frame: Up to one year
|
All events which do not fall under characterization of major bleeding events as explained in section "primary outcome variables"
|
Up to one year
|
Start of rivaroxaban therapy and, if applicable, stop of rivaroxaban therapy
Time Frame: Up to one year
|
Start date and stop date will be collected to receive information on drug persistence
|
Up to one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2017
Primary Completion (Actual)
August 9, 2019
Study Completion (Actual)
November 20, 2019
Study Registration Dates
First Submitted
September 14, 2017
First Submitted That Met QC Criteria
September 14, 2017
First Posted (Actual)
September 15, 2017
Study Record Updates
Last Update Posted (Actual)
November 24, 2020
Last Update Submitted That Met QC Criteria
November 20, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Arrhythmias, Cardiac
- Embolism
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
Other Study ID Numbers
- 18981
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing".
This pertains to scope, time point and process of data access.
As such, Bayer commits to sharing upon request from qualified researcher's patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research.
This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research.
Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Rivaroxaban (Xarelto, BAY59-7939)
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
BayerJanssen Research & Development, LLCCompletedVenous ThrombosisFrance, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
-
BayerJanssen Research & Development, LLCCompletedNon-valvular Atrial FibrillationItaly
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationAustria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
-
BayerJanssen Research & Development, LLC; RTI Health SolutionsCompletedAnticoagulationGermany, United Kingdom, France, Spain
-
BayerJanssen Research & Development, LLCCompleted
-
BayerJanssen Research & Development, LLCCompletedThrombosisCanada, United States, Belgium, Spain, Italy, France, Finland, Hungary
-
BayerJanssen Research & Development, LLCCompleted
-
BayerJanssen Research & Development, LLCCompletedVenous ThromboembolismSwitzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
-
BayerJanssen Research & Development, LLCCompletedAtrial FibrillationIndonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam